Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 ... The market for injectable anti-obesity drugs, currently dominated by Zepbound (made by Lilly) and Wegovy ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked ... Lilly is running to test the drug, called orforglipron, in diabetes, obesity and other related ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

According to the US government’s clinical trial registry, Lilly’s primary obesity trial is not expected to conclude until at least July. An oral version of weight loss drugs could pose a ...

Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo ...

Orforglibron, a pill form of GLP-1 weight loss ... diabetes. Lilly plans to seek approval from the U.S. Food and Drug Administration later this year to offer orforglipron for obesity, and early ...

Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative.